Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BHST NASDAQ:CNTX NASDAQ:INKT NASDAQ:MBRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHSTBioHarvest Sciences$2.87$3.58$2.74▼$12.80$56.30M0.8723,622 shs1,039 shsCNTXContext Therapeutics$0.65$1.77$0.55▼$3.62$60.06M1.754.10 million shs2.59 million shsINKTMiNK Therapeutics$11.67$11.53$6.80▼$76.00$58.14M0.4725,112 shs7,601 shsMBRXMoleculin Biotech$2.64$2.59$1.79▼$24.00$14.09M1.751.12 million shs352,660 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHSTBioHarvest Sciences0.00%+2.32%-11.69%-32.94%-57.92%CNTXContext Therapeutics0.00%+12.71%-67.80%-75.97%+3.47%INKTMiNK Therapeutics0.00%+0.26%-8.47%+9.17%+60.41%MBRXMoleculin Biotech0.00%-19.27%+5.18%+13.79%-69.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHSTBioHarvest Sciences$2.87$3.58$2.74▼$12.80$56.30M0.8723,622 shs1,039 shsCNTXContext Therapeutics$0.65$1.77$0.55▼$3.62$60.06M1.754.10 million shs2.59 million shsINKTMiNK Therapeutics$11.67$11.53$6.80▼$76.00$58.14M0.4725,112 shs7,601 shsMBRXMoleculin Biotech$2.64$2.59$1.79▼$24.00$14.09M1.751.12 million shs352,660 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHSTBioHarvest Sciences0.00%+2.32%-11.69%-32.94%-57.92%CNTXContext Therapeutics0.00%+12.71%-67.80%-75.97%+3.47%INKTMiNK Therapeutics0.00%+0.26%-8.47%+9.17%+60.41%MBRXMoleculin Biotech0.00%-19.27%+5.18%+13.79%-69.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHSTBioHarvest Sciences 2.00Hold$10.00248.43% UpsideCNTXContext Therapeutics 2.89Moderate Buy$6.17843.35% UpsideINKTMiNK Therapeutics 2.40Hold$35.00199.91% UpsideMBRXMoleculin Biotech 2.33Hold$22.00733.33% UpsideCurrent Analyst Ratings BreakdownLatest MBRX, BHST, INKT, and CNTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026BHSTBioHarvest Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/17/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/16/2026CNTXContext Therapeutics Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $4.006/3/2026BHSTBioHarvest Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/27/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/18/2026INKTMiNK Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.005/12/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/24/2026INKTMiNK Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026MBRXMoleculin Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026CNTXContext Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHSTBioHarvest Sciences$34.51M1.63N/AN/A$1.30 per share2.21CNTXContext TherapeuticsN/AN/AN/AN/A$0.66 per shareN/AINKTMiNK TherapeuticsN/AN/AN/AN/A($3.03) per shareN/AMBRXMoleculin BiotechN/AN/AN/AN/A$4.69 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHSTBioHarvest Sciences-$11.14M-$0.59N/AN/AN/A-32.54%-76.03%-25.30%8/10/2026 (Estimated)CNTXContext Therapeutics-$36.12M-$0.42N/AN/AN/AN/A-59.95%-54.78%8/5/2026 (Estimated)INKTMiNK Therapeutics-$12.49M-$2.84N/AN/AN/AN/AN/A-118.57%8/13/2026 (Estimated)MBRXMoleculin Biotech-$33.56M-$17.98N/AN/AN/AN/AN/A-70.93%8/11/2026 (Estimated)Latest MBRX, BHST, INKT, and CNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026INKTMiNK Therapeutics-$0.77-$0.57+$0.20-$0.57N/AN/A5/14/2026Q1 2026BHSTBioHarvest Sciences-$0.13-$0.11+$0.02-$0.11$8.50 million$8.51 million5/14/2026Q1 2026MBRXMoleculin Biotech-$2.3333-$3.54-$1.2067-$3.54N/AN/A5/6/2026Q1 2026CNTXContext Therapeutics-$0.12-$0.09+$0.03-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBHSTBioHarvest SciencesN/AN/AN/AN/AN/ACNTXContext TherapeuticsN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHSTBioHarvest Sciences0.032.962.44CNTXContext TherapeuticsN/A8.968.96INKTMiNK TherapeuticsN/A1.381.38MBRXMoleculin BiotechN/A1.381.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHSTBioHarvest SciencesN/ACNTXContext Therapeutics14.03%INKTMiNK Therapeutics2.87%MBRXMoleculin Biotech15.52%Insider OwnershipCompanyInsider OwnershipBHSTBioHarvest SciencesN/ACNTXContext Therapeutics4.80%INKTMiNK Therapeutics20.40%MBRXMoleculin Biotech1.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHSTBioHarvest SciencesN/A19.62 millionN/AN/ACNTXContext Therapeutics791.88 million87.47 millionNot OptionableINKTMiNK Therapeutics304.98 million3.97 millionNo DataMBRXMoleculin Biotech205.34 million5.28 millionNot OptionableMBRX, BHST, INKT, and CNTX HeadlinesRecent News About These CompaniesMBRX stock drops 25% as Moleculin Biotech's interim cancer trial data falls short of significanceJuly 1, 2026 | msn.comWhy is Moleculin Stock Falling Today?June 30, 2026 | benzinga.comMoleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than ControlJune 30, 2026 | globenewswire.comMoleculin Biotech Insider Trading Activity | NASDAQ:MBRX | BenzingaJune 25, 2026 | benzinga.comIndependent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AMLJune 5, 2026 | globenewswire.comMoleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” SegmentJune 4, 2026 | globenewswire.comMoleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline LimitsMay 29, 2026 | globenewswire.comMoleculin Biotech Releases Updated Investor Information PresentationMay 26, 2026 | tipranks.comMoleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for AnnamycinMay 21, 2026 | globenewswire.comMoleculin Biotech Reports Promising Early Results in MIRACLE Trial for AML Treatment with 40% Composite Complete Remission RateMay 15, 2026 | quiverquant.comQMoleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE TrialMay 15, 2026 | globenewswire.comMoleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical BenchmarksMay 13, 2026 | globenewswire.comIndependent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline LimitsMay 12, 2026 | globenewswire.comMoleculin Biotech Secures Hong Kong Patent for Annamycin Method Ahead of Phase 3 Clinical Data ReleaseMay 8, 2026 | quiverquant.comQMoleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of AnnamycinMay 8, 2026 | globenewswire.comMoleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026April 24, 2026 | markets.businessinsider.comMoleculin Biotech, Inc. Reports Promising Preclinical Results for Annamycin in Pancreatic Cancer TreatmentApril 23, 2026 | quiverquant.comQMoleculin's Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026April 23, 2026 | globenewswire.comMoleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual MeetingApril 21, 2026 | globenewswire.comMoleculin Biotech Stockholders Approve Warrant Share IssuanceApril 15, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMBRX, BHST, INKT, and CNTX Company DescriptionsBioHarvest Sciences NASDAQ:BHST$2.87 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$2.88 +0.01 (+0.38%) As of 07/2/2026 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.Context Therapeutics NASDAQ:CNTX$0.65 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$0.65 0.00 (-0.11%) As of 07/2/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.MiNK Therapeutics NASDAQ:INKT$11.67 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$11.63 -0.04 (-0.31%) As of 07/2/2026 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.Moleculin Biotech NASDAQ:MBRX$2.64 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$2.59 -0.05 (-1.93%) As of 07/2/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
